<DOC>
	<DOCNO>NCT00269867</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness infliximab ( anti-TNF chimeric monoclonal antibody [ cA2 ] ) patient active Rheumatoid Arthritis , despite methotrexate treatment .</brief_summary>
	<brief_title>Infliximab Plus Methotrexate Treatment Rheumatoid Arthritis</brief_title>
	<detailed_description>This placebo-controlled , double-blinded , randomized clinical study evaluate safety effectiveness infliximab patient active Rheumatoid Arthritis , despite methotrexate treatment . Infliximab anti-TNF chimeric monoclonal antibody ( cA2 ) . The primary measure effectiveness include change baseline American College Rheumatology ( ACR20 ) response week 30 , change modify van der Heijde Sharp Score . The ACR20 Responder Index composite clinical , laboratory , functional measure van der Heijde-Sharp ( vdH-S ) score method method rating structural damage patients.. Patients treat either infliximab match placebo .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients active Rheumatoid Arthritis despite treatment methotrexate Diagnosed Rheumatoid Arthritis least 6 month prior screen Having active disease time screen preinfusion define least 6 swollen joint 6 tender joint Using methotrexate least 3 month prior study enrollment Patients systemic inflammatory condition Having Lyme disease rheumatic disease Rheumatoid Arthritis Who use DiseaseModifying Antirheumatic Drugs ( DMARDs ) methotrexate within 4 week prior screen Who use corticosteroid within 4 week prior screen Having receive previous administration infliximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>infliximab</keyword>
	<keyword>methotrexate</keyword>
</DOC>